Long Term Survival of Lung Transplant Recipients After Implementation of Lung Allocation Score.

2014 ◽  
Vol 98 ◽  
pp. 802
Author(s):  
J. Mooney ◽  
B. Maxwell ◽  
J. Levitt ◽  
B. Goldstein ◽  
M. Nicolls ◽  
...  
Author(s):  
Johanna M. Kwakkel-van Erp ◽  
Annelieke W. Paantjens ◽  
Diana A. van Kessel ◽  
Jules M.M. van den Bosch ◽  
Jan C. Grutters ◽  
...  

2017 ◽  
Vol 31 (5) ◽  
pp. e12953 ◽  
Author(s):  
Asishana A. Osho ◽  
Sameer A. Hirji ◽  
Anthony W. Castleberry ◽  
Michael S. Mulvihill ◽  
Asvin M. Ganapathi ◽  
...  

2010 ◽  
Vol 29 (2) ◽  
pp. S134-S134
Author(s):  
J.M. Kwakkel-van Erp ◽  
E.A. van de Graaf ◽  
A.W.M. Paantjens ◽  
D.A. van Kessel ◽  
J.M.M. van den Bosch ◽  
...  

2021 ◽  
Vol 40 (4) ◽  
pp. S159
Author(s):  
L.M. Piechura ◽  
F. Yazdchi ◽  
M.T. Harloff ◽  
H. Shim ◽  
N.S. Sharma ◽  
...  

2020 ◽  
Vol 9 (7) ◽  
pp. 2307
Author(s):  
Yan Y. Sanders

The main challenge for a positive long-term outcome in lung transplantation is the lack of early detection for chronic lung allograft dysfunction (CLAD). With advancements in technology, an increasing number of studies demonstrate that cell-free DNA (cfDNA) in body fluids could be used as a marker for disease diagnosis, prognosis or monitoring response to treatment. A previous report from this journal found the joint assessment of cfDNA and CXCL10 from brochoalveolar lavage (BAL) could determine the subphenotypes of CLAD and predict lung transplant survival. This is an exciting attempt in monitoring the progress for lung transplant recipients. More studies and better understanding of cfDNA are needed to develop an accessible and reliable biomarker to monitor the progress of CLAD to improve the long-term survival for lung transplant recipients.


2021 ◽  
Vol 40 (4) ◽  
pp. S72
Author(s):  
J. Fernandez-Castillo ◽  
E. Huszti ◽  
L. Levy ◽  
R. Ghany ◽  
P. Riddell ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document